AC Immune S.A. (ACIU) Stock Analysis & Investment Frameworks
AC Immune S.A. (ACIU) stock analysis on Invetso. Review AC Immune S.A.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
AC Immune S.A. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CH
AC Immune S.A. Key Financial Metrics
- Market Cap: $246.29M
- Revenue: $4.33M
- ROE: -99.17%
- ROIC: -86.61%
- Dividend Yield: N/A
About AC Immune S.A.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
AC Immune S.A. Investment Frameworks
Invetso analyzes AC Immune S.A. (ACIU) across the following frameworks:
- AC Immune S.A. 10Y Growth Potential
- AC Immune S.A. Scenario Analysis
- AC Immune S.A. Risks & Opportunities
- AC Immune S.A. Economic Moat
- AC Immune S.A. Business Model
- AC Immune S.A. Management
- AC Immune S.A. SWOT Analysis
- AC Immune S.A. Porter's 5 Forces
- AC Immune S.A. PESTLE Analysis
- AC Immune S.A. ESG Analysis